Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today ...

Even though lung and related cancer deaths decreased in the world's 10 most populous countries from 1990 to 2019, these positive statistics do not address trends in mortality linked to tobacco use, ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...